IL17A and gout: In contrast, in Tregs from gout flare versus remission, the IL-17, NOD-like receptor, and MAPK signaling pathways were enriched, whereas the cGMP-PKG, FoxO, and cAMP signaling pathways were significantly inhibited (Supplemental Figure 4D).